Emerald’s values, sustainable grow and leadership

Get a prescription and have your prescription filled for medical cannabis with Emerald

Emerald’s dried flower and extract products for the recreational market

FEATUring ouR

Sync product line

Balancing daily responsibilities and taking time for self-care can be a struggle; sometimes you need a little help relaxing your mind and body. The SYNCTM portfolio includes an array of smoke-free all-natural products that come in different potencies and flavours. We’ve elevated our select flavoured products with similar tasting terpenes that enhance user experience. Terpenes are naturally occurring compounds found in certain plants that have therapeutic effects. Get in SYNC and harmonize your wellness routines.

SYNC 100

SYNC 100 Full Flower Cannabis Oil from Emerald Health

One of the most potent CBD oil formulas on the market, SYNC 100 CBDTM contains approximately 2000 mg of CBD per bottle. It is formulated with whole-flower extract and organic coconut oil (palm free) for excellent quality and natural flavour.


Nano THC CBD Backdrop 7x7 1

SYNCTM Nano Fast-Action Sprays use nanoemulsion technology to achieve faster and more predictable effects. 


SYNC Wellness Products

We use all-natural ingredients in our select flavoured products and plant-based terpenes that enhance user experience.

Landing Page Patients


Prescriptions and Patient Registration

Do you have a prescription for medical cannabis and want to get it filled? Register as a patient with Emerald in three simple steps and access our excellent selection of medical cannabis products. If you don’t have a prescription, apply for online consultation with a certified health care practitioner. 


Emerald Health Therapeutics, Inc. is publicly traded on the TSXV (EMH) and the OTCQX (EMHTF). Visit our Investors page for the latest news releases, financial reports and more – everything you need to know to invest with confidence.

Asian Man Investors Section PNG
Drop logo greenhouse texture 1


Orville Bovenschen

Senior Vice President, Operations

Mr. Bovenschen has over 16 years of progressive experience in financial management, project and operations management, strategy development and risk management. Before joining Emerald, he was a senior member of the construction joint venture responsible for the Riyadh metro project, a rapid transit system under construction in Saudi Arabia with a US$22B contract value. Mr. Bovenschen previously served in various management roles for Strukton, a leading construction and engineering firm in the Netherlands and earned a Master of Business Administration from Nyenrode Business University and a BBA from NCOI in Utrecht, Netherlands.

Rebecca Wong

Senior Vice President, Quality and Regulatory Affairs

Ms. Wong has over 30 years of quality and regulatory management experience in pharmaceutical and life science companies regulated to Canadian, US, European and international requirements. She has been responsible for establishing quality systems and ensuring regulatory compliance through all phases of product development from GPP, GLP, GCP, GMP for cannabis, pharmaceuticals, medical devices, combination products and biologicals. She was previously Executive Director of Quality Assurance at Novelion Therapeutics (formerly QLT Inc.) and worked for life science companies including MDS Nordion, Cangene Corporation, and Biomira Inc. Ms. Wong earned a B.Sc. (Microbiology) from the University of Alberta.

Jenn Hepburn

Chief Financial Officer

Ms. Hepburn has over a decade of experience in accounting and finance and is an experienced manager of privately and publicly traded manufacturing and mining businesses operating in Canada and the USA. Prior to joining Emerald, Ms. Hepburn was the Director of Finance and Administration at bioLytical Laboratories Inc., a medical diagnostics manufacturer. Before that, she held controller positions at junior gold and silver mining companies Northern Vertex Mining Corp., Kootenay Silver Inc. and Theia Resources Ltd. Ms. Hepburn earned a BBA from Simon Fraser University and her certification from the Certified Management Accountants of British Columbia.


President & Chief Executive Officer

Mr. Bandali’s expertise in global operations, strategy development, driving innovation, M&A, and investment management has been developed over a 25-year career in the life sciences sector spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.

He holds an Advanced Management Program Degree from Harvard Business School, a Master of Business Administration from McGill University, and a Bachelor of Science from the University of British Columbia. He is an innovative business leader who has built strategic and operating plans that have resulted in rapid growth and significant profitability enhancement. He has managed businesses and operations with a global footprint and has led teams of over 900 people.

Mr. Bandali’s previous experience includes serving as President, Early Phase Clinical Services and Translational Science, Syneos Health; President, Early Stage Development, as well as Chief Innovation Officer, inVentiv Health Clinical; Senior Vice President, Strategy and Business Development, AB Sciex and Molecular Devices (part of Danaher Corporation); Senior Vice President, Strategy, Legal and Corporate Development, MDS Analytical Technologies; and Vice President and General Manager, Global Early Stage Development, MDS Pharma Services. He was also Venture Partner and Vice President at MDS Capital and has served on the boards of private and public companies.